Navigation Links
MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients
Date:12/13/2007

rint(R) is a powerful predictor of disease outcome in lymph node positive breast cancer patients," said Prof. Dr. Rene Bernards, chief scientific officer at Agendia. "Based on these data, the inclusion criteria of the large MINDACT clinical trial using MammaPrint(R) will be enlarged to include patients with 1-3 positive nodes."

Agendia will start offering MammaPrint(R) to patients having 1-3 positive lymph nodes in Europe. These data will also be submitted to the U.S. Food and Drug Administration (FDA) for regulatory approval at a later date.

About MammaPrint(R)

MammaPrint(R) laboratory service is the first and only FDA cleared (February 2007) DNA microarray-based 'in vitro diagnostic multivariate index assay' (IVDMIA). MammaPrint(R) measures the activity of 70 genes, providing information about the likelihood of tumor recurrence. The MammaPrint(R) test measures the level of expression of each of these genes in a sample of a woman's surgically-removed breast cancer tumor and then uses a specific formula or algorithm to produce a score that determines whether the patient is deemed low risk or high risk for spread of the cancer to another site. The result may help a doctor in planning treatment and appropriate follow-up for a patient when used with other clinical information and laboratory tests. All MammaPrint(R) tests are conducted in Agendia's CLIA-certified central service laboratory.

About Agendia

Agendia, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to receive FDA approval for its breast cancer test -- MammaPrint(R) -- that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)*, is a diagnostic test to identify the origin of a metastasis in a cancer type
'/>"/>

SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
4. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
5. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
6. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
7. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
8. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
11. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 ... clinical-stage pharmaceutical company focused on the development of oral ... Nadav Kidron will present at FireRock Capital,s ... Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ... New York City , ...
(Date:10/25/2014)... Investor-Edge has initiated coverage on the following ... Pharmaceuticals Inc. (NASDAQ: VRTX ), Alexion Pharmaceuticals ... (NASDAQ: PPHM ), and StemCells Inc. (NASDAQ: ... accessed at: http://investor-edge.com/register . The US ... positive note as the Dow Jones Industrial Average finished ...
(Date:10/22/2014)... 2014 New test innovations will be the ... (IVD) test industry, especially as companies struggle with reimbursement ... more than 25 testing innovations in important disease areas ... IVD products. Kalorama details the new approaches its biennial survey ... In Vitro Diagnostic Tests , 9th Edition . ...
(Date:10/22/2014)... 21, 2014 The Americas Inorganic ... refrigerants market in Americas with analysis and forecast ... the Americas Inorganic Refrigerants Market report, to get ... also provides a glimpse of the segmentation in ... by various tables and figures. , ...
Breaking Biology Technology:Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3
... SAN DIEGO, March 29, 2011 Marshall Edwards, Inc.(Nasdaq: ... the clinical development of novel therapeutics targeting cancer metabolism, ... inhibitor program has been accepted for a late-breaking poster ... Annual Meeting on Monday, April 4, 2011 at 1:00 ...
... EXTON, Pa., March 29, 2011 Morphotek®, Inc., ... it has entered into a collaboration and license ... the parties will collaborate to develop and commercialize ... monoclonal antibody to specifically detect human folate receptor ...
... DIEGO, March 29, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the American College of Cardiology (ACC) ... ACC:  Ernest N. Morial Convention Center (Expo Hall), New ...
Cached Biology Technology:Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 2Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 3Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 2Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 3
(Date:10/17/2014)... news release is available in German . ... only a very few drugs. When treating overdoses, doctors are ... is especially difficult if there is a combination of drugs ... playing and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe ... wanted to find an answer to this question. "The task ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... Gene scanning techniques developed by Professor Ian Day and ... have a major impact on healthcare in the future. ... by Professor Day and his team in the Human ... been successfully applied to search for rare genetic mutations ...
... volume says Dutch researcher Bas Tomassen. He investigated the uptake ... and human cells. , Cell volume is the outcome ... the cell plasma membrane. A cell can regulate its volume ... Exactly how this process works is still not known. Bas ...
... Scientists at the Albert Einstein College of Medicine have ... causes tuberculosis may soon be able to resist the ... why several disease-causing microbes, including Shigella and E. coli, ... research effort was led by Dr. John S. Blanchard, ...
Cached Biology News:New gene scanning technology marks a major advance in disease research 2Water management in cells 2Einstein researchers identify new way that bacteria develop resistance to antibiotics 2
... 5'GCCNNNN NGGC3' 3'CGGN NNNNCCG5' Inactivation Conditions: Heat ... phenol treatment followed by ethanol precipitation. Storage ... 0.1mM EDTA, 1.0mM DTT, 0.01% BSA, 50% ... ice. Store at -20C. Unit Definition: One ...
...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... Plus DNA Polymerase with a proprietary thermostable ... fidelity than standard Taq DNA polymerase, Double ... Amplifies DNA templates >20kb, Concentration: 5U/ul, Applications: ... cloning and mutagenesis We are part of ...
Biology Products: